



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

September 2018





HIV/AIDS Drug Treatment Program

Monthly Report

© 2018 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

September 2018

N = 7248



Health Authority	Male	Female	All
FRASER	1416	403	1819
INTERIOR	385	99	484
NORTHERN	131	81	212
VANCOUVER COASTAL	3383	446	3829
VANCOUVER ISLAND	724	146	870
	6039	1175	7214
		Unknown/not stated:	34
		Total:	7248

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (September 2013 - September 2018)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (September 2013 - September 2018)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (September 2013 - September 2018)






1.5 BC-CfE Enrollment: New Antiretroviral Participants
(September 2013 - September 2018)






1.6 Percent Distribution of Active Participants by CD4 Count (September 2013 - September 2018)






1.7 Percent Distribution of Inactive Participants by CD4 Count (September 2013 - September 2018)






1.8 Active and Inactive Participants (September 2013 - September 2018)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (September 2013 - September 2018)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (September 2013 - September 2018)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(September 2013 - September 2018)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (September 2013 - September 2018)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(September 2013 - September 2018)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (September 2013 - September 2018)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(September 2013 - September 2018)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (September 2013 - September 2018)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(September 2013 - September 2018)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts (September 2013 - September 2018)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(September 2013 - September 2018)**






1.20 Cumulative Resistance Testing Results by Resistance Category (September 2013 - September 2018)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (September 2013 - September 2018)





2.1 Duration of ARV treatment in the Province of BC, 1987-2018 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	26	5	0	5	5	760	5	<40	3
1988	27	7	0	7	7	510	7	<40	3
1989	25	54	2	56	46	485	52	<40	3
1990	24	57	1	58	55	520	58	<40	3
1991	24	38	3	41	32	570	41	<40	3
1992	24	65	7	72	54	580	70	<40	3
1993	23	138	15	153	139	560	149	<40	3
1994	22	79	11	90	77	590	87	<40	3
1995	22	130	22	152	127	580	145	<40	3
1996	20	361	58	419	366	590	403	<40	3
1997	18	295	34	329	288	630	313	<40	3
1998	17	208	47	255	213	560	245	<40	3
1999	17	166	40	206	180	560	196	<40	3
2000	17	124	33	157	132	600	149	<40	3
2001	17	122	32	154	127	570	145	<40	3
2002	16	128	26	154	127	570	150	<40	3
2003	15	160	25	185	153	610	178	<40	3
2004	14	167	41	208	173	590	197	<40	3
2005	13	185	46	231	206	602	225	<40	3
2006	12	196	39	235	189	570	222	<40	3
2007	11	262	48	310	258	610	295	<40	3
2008	10	290	64	354	296	670	335	<40	3
2009	9	329	69	398	340	645	372	<40	3
2010	8	285	68	353	307	660	339	<40	3
2011	7	329	72	401	334	670	370	<40	3
2012	6	287	62	349	288	700	334	<40	3
2013	5	284	66	350	292	670	329	<40	3
2014	4	293	48	341	280	695	328	<40	3
2015	3	289	49	338	265	670	307	<40	3
2016	2	286	60	346	285	670	324	<40	3
2017	1	247	41	288	243	620	275	<40	3
2018	0	182	43	225	206	555	218	<40	3
Total:		6048	1172	7220					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	7182	747	2326	<40	2077	590
FEB-2017	7134	754	1914	<40	1739	590
MAR-2017	7186	744	2204	<40	2018	600
APR-2017	7178	746	1966	<40	1770	590
MAY-2017	7224	744	2276	<40	2057	590
JUN-2017	7245	752	2120	<40	1953	596
JUL-2017	7241	753	1965	<40	1789	580
AUG-2017	7266	757	2106	<40	1884	590
SEP-2017	7222	762	2042	<40	1837	610
OCT-2017	7244	770	2187	<40	1938	610
NOV-2017	7241	766	2074	<40	1874	610
DEC-2017	7227	775	1740	<40	1536	610
JAN-2018	7292	756	2385	<40	2102	610
FEB-2018	7256	765	1904	<40	1740	610
MAR-2018	7281	774	2050	<40	1820	619
APR-2018	7266	781	2082	<40	1831	620
MAY-2018	7288	781	2149	<40	1905	600
JUN-2018	7295	795	2010	<40	1764	610
JUL-2018	7297	797	2038	<40	1762	600
AUG-2018	7288	801	2090	<40	1785	620
SEP-2018	7248	803	2011	<40	1662	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	1402	3157	88	140	80	417
FEB-2017	1455	2851	80	1874	70	400
MAR-2017	1408	3137	99	635	89	380
APR-2017	1423	3092	94	545	85	420
MAY-2017	1394	3284	85	180	75	420
JUN-2017	1384	3368	76	197	68	485
JUL-2017	1404	3259	67	436	60	500
AUG-2017	1397	3352	78	160	68	495
SEP-2017	1454	3064	74	323	66	415
OCT-2017	1428	3244	91	218	80	470
NOV-2017	1447	3144	79	144	68	360
DEC-2017	1478	3043	60	53	50	382
JAN-2018	1431	3297	78	872	70	365
FEB-2018	1476	3102	79	1036	65	440
MAR-2018	1460	3180	75	59	70	485
APR-2018	1479	3151	72	634	61	500
MAY-2018	1462	3229	91	<40	81	460
JUN-2018	1468	3235	66	4750	60	425
JUL-2018	1476	3251	69	<40	55	540
AUG-2018	1522	3097	66	52	54	487
SEP-2018	1564	2916	93	127	80	420

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2017	7140	1402	21	21	141	142	-6	12876
FEB-2017	7102	1455	10	24	136	182	-38	12910
MAR-2017	7147	1408	17	19	189	139	45	12936
APR-2017	7139	1423	12	20	143	151	-8	12968
MAY-2017	7194	1394	7	22	170	126	55	13002
JUN-2017	7209	1384	10	24	151	138	15	13032
JUL-2017	7202	1404	7	14	134	142	-7	13051
AUG-2017	7229	1397	10	25	156	137	27	13081
SEP-2017	7185	1454	12	16	137	180	-44	13110
OCT-2017	7212	1428	7	6	184	151	27	13123
NOV-2017	7206	1447	16	19	142	148	-6	13158
DEC-2017	7197	1478	5	18	157	175	-9	13189
JAN-2018	7252	1431	13	12	192	128	55	13218
FEB-2018	7220	1476	11	27	123	168	-32	13255
MAR-2018	7241	1460	17	22	153	133	21	13283
APR-2018	7231	1479	13	14	152	159	-10	13304
MAY-2018	7259	1462	9	12	171	144	28	13329
JUN-2018	7260	1468	13	16	149	149	1	13351
JUL-2018	7260	1476	13	15	156	155	0	13378
AUG-2018	7258	1522	9	27	155	173	-2	13417
SEP-2018	7220	1564	16	15	159	194	-38	13443

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2017	61	6615	443	63	7182	0.85%	92.11%	6.17%	0.88%	100.00%
FEB-2017	60	6579	440	55	7134	0.84%	92.22%	6.17%	0.77%	100.00%
MAR-2017	60	6629	439	58	7186	0.83%	92.25%	6.11%	0.81%	100.00%
APR-2017	58	6633	428	59	7178	0.81%	92.41%	5.96%	0.82%	100.00%
MAY-2017	62	6665	438	59	7224	0.86%	92.26%	6.06%	0.82%	100.00%
JUN-2017	57	6691	438	59	7245	0.79%	92.35%	6.05%	0.81%	100.00%
JUL-2017	61	6685	433	62	7241	0.84%	92.32%	5.98%	0.86%	100.00%
AUG-2017	61	6696	448	61	7266	0.84%	92.16%	6.17%	0.84%	100.00%
SEP-2017	57	6677	431	57	7222	0.79%	92.45%	5.97%	0.79%	100.00%
OCT-2017	58	6691	438	57	7244	0.80%	92.37%	6.05%	0.79%	100.00%
NOV-2017	59	6681	445	56	7241	0.81%	92.27%	6.15%	0.77%	100.00%
DEC-2017	58	6666	447	56	7227	0.80%	92.24%	6.19%	0.77%	100.00%
JAN-2018	58	6728	451	55	7292	0.80%	92.27%	6.18%	0.75%	100.00%
FEB-2018	61	6685	451	59	7256	0.84%	92.13%	6.22%	0.81%	100.00%
MAR-2018	62	6710	453	56	7281	0.85%	92.16%	6.22%	0.77%	100.00%
APR-2018	58	6701	449	58	7266	0.80%	92.22%	6.18%	0.80%	100.00%
MAY-2018	62	6712	456	58	7288	0.85%	92.10%	6.26%	0.80%	100.00%
JUN-2018	60	6728	449	58	7295	0.82%	92.23%	6.15%	0.80%	100.00%
JUL-2018	52	6730	460	55	7297	0.71%	92.23%	6.30%	0.75%	100.00%
AUG-2018	53	6725	454	56	7288	0.73%	92.27%	6.23%	0.77%	100.00%
SEP-2018	51	6679	459	59	7248	0.70%	92.15%	6.33%	0.81%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3114 45%	12 38%	2834 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3962 57%
MAY-2017	9 26%	3159 45%	9 26%	2881 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3930 56%
JUN-2017	6 20%	3169 45%	6 20%	2902 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3898 55%
JUL-2017	7 37%	3198 46%	7 37%	2928 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%
AUG-2017	6 20%	3224 46%	4 13%	2958 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3838 54%
SEP-2017	10 34%	3213 46%	10 34%	2950 42%	0 0%	66 1%	0 0%	5 0%	0 0%	4 0%	3 10%	207 3%	16 55%	3775 54%
OCT-2017	5 38%	3241 46%	5 38%	2983 42%	0 0%	65 1%	0 0%	4 0%	0 0%	4 0%	2 15%	245 3%	6 46%	3715 53%
NOV-2017	9 26%	3281 47%	8 23%	3025 43%	0 0%	65 1%	0 0%	5 0%	0 0%	4 0%	1 3%	265 4%	25 71%	3661 52%
DEC-2017	10 32%	3286 47%	10 32%	3032 43%	0 0%	64 1%	0 0%	5 0%	0 0%	4 0%	1 3%	272 4%	22 71%	3612 52%
JAN-2018	10 36%	3319 47%	9 32%	3075 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3635 51%
FEB-2018	13 35%	3320 47%	12 32%	3078 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3587 51%
MAR-2018	10 36%	3341 47%	10 36%	3105 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	18 64%	3569 50%
APR-2018	5 24%	3348 47%	5 24%	3116 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 10%	333 5%	14 67%	3541 50%
MAY-2018	9 39%	3355 47%	8 35%	3129 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3518 50%
JUN-2018	6 30%	3373 48%	6 30%	3149 44%	0 0%	54 1%	0 0%	5 0%	0 0%	3 0%	1 5%	380 5%	13 65%	3488 49%
JUL-2018	7 27%	3399 48%	7 27%	3176 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 15%	398 6%	15 58%	3454 49%
AUG-2018	13 33%	3395 48%	14 36%	3183 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	414 6%	23 59%	3412 48%
SEP-2018	4 15%	3383 48%	3 12%	3169 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	445 6%	18 69%	3368 48%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3791	55%
MAY-2017	25	74%	3795	54%
JUN-2017	24	80%	3797	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3767	53%
SEP-2017	19	66%	3740	53%
OCT-2017	7	54%	3731	53%
NOV-2017	26	74%	3693	53%
DEC-2017	21	68%	3665	52%
JAN-2018	18	64%	3711	52%
FEB-2018	24	65%	3681	52%
MAR-2018	18	64%	3675	52%
APR-2018	16	76%	3663	52%
MAY-2018	14	61%	3664	52%
JUN-2018	14	70%	3665	52%
JUL-2018	19	73%	3656	52%
AUG-2018	25	64%	3644	51%
SEP-2018	22	85%	3626	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1484 49%	5 71%	1318 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1350 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1359 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1439 47%	6 100%	1359 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1417 47%	21 95%	1396 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
SEP-2017	0 0%	9 0%	0 0%	1388 46%	8 100%	1389 46%	0 0%	210 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
OCT-2017	0 0%	8 0%	0 0%	1364 46%	6 100%	1396 47%	0 0%	207 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
NOV-2017	0 0%	8 0%	1 8%	1324 45%	10 83%	1392 48%	1 8%	206 7%	0 0%	3 0%	0 0%	1 0%	0 0%	10 0%
DEC-2017	0 0%	7 0%	1 7%	1295 45%	14 93%	1397 48%	0 0%	197 7%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JAN-2018	0 0%	8 0%	3 30%	1318 45%	7 70%	1418 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1259 44%	15 100%	1422 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1248 43%	10 91%	1439 50%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1224 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1212 43%	5 100%	1443 51%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1191 42%	11 92%	1436 51%	0 0%	177 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 18%	1170 42%	8 73%	1445 52%	1 9%	170 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1154 42%	11 69%	1427 52%	0 0%	165 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1131 42%	6 86%	1410 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%
SEP-2017	0	0%	1	0%
OCT-2017	0	0%	1	0%
NOV-2017	0	0%	1	0%
DEC-2017	0	0%	1	0%
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	897 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	888 40%	0 0%	273 12%	1 11%	787 36%	4 44%	271 12%
MAY-2017	3 75%	877 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	838 39%	0 0%	264 12%	0 0%	779 36%	0 0%	283 13%
AUG-2017	1 100%	821 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%
SEP-2017	4 50%	808 38%	0 0%	264 12%	1 13%	774 36%	3 38%	296 14%
OCT-2017	1 100%	802 38%	0 0%	267 13%	0 0%	768 36%	0 0%	299 14%
NOV-2017	5 71%	800 38%	0 0%	269 13%	0 0%	767 36%	2 29%	300 14%
DEC-2017	3 75%	793 38%	0 0%	263 12%	0 0%	758 36%	1 25%	301 14%
JAN-2018	3 50%	779 37%	1 17%	263 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	746 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	722 36%	0 0%	248 12%	0 0%	725 36%	1 50%	314 16%
JUL-2018	3 60%	724 36%	0 0%	243 12%	0 0%	717 36%	2 40%	314 16%
AUG-2018	2 100%	715 36%	0 0%	238 12%	0 0%	715 36%	0 0%	308 16%
SEP-2018	6 100%	706 36%	0 0%	236 12%	0 0%	710 36%	0 0%	311 16%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	0 0%	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	0 0%	0 0%	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	0 0%	0 0%	13 87%	1620 55%	2 13%	601 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	0 0%	0 0%	14 78%	1655 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	0 0%	0 0%	19 86%	1726 57%	3 14%	602 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	0 0%	0 0%	12 75%	1757 57%	3 19%	596 19%	0 0%	49 2%	1 6%	713 23%	0 0%	1 0%
JUL-2017	0 0%	0 0%	8 73%	1791 58%	3 27%	592 19%	0 0%	48 2%	0 0%	705 23%	0 0%	1 0%
AUG-2017	0 0%	0 0%	13 72%	1824 58%	4 22%	596 19%	0 0%	49 2%	1 6%	707 22%	0 0%	1 0%
SEP-2017	0 0%	0 0%	10 71%	1833 58%	4 29%	600 19%	0 0%	50 2%	0 0%	700 22%	0 0%	1 0%
OCT-2017	0 0%	0 0%	8 89%	1879 59%	1 11%	608 19%	0 0%	48 1%	0 0%	708 22%	0 0%	0 0%
NOV-2017	0 0%	0 0%	14 67%	1939 60%	5 24%	611 19%	0 0%	49 2%	2 10%	701 22%	0 0%	0 0%
DEC-2017	0 0%	0 0%	11 69%	1958 60%	5 31%	603 18%	0 0%	48 1%	0 0%	689 21%	0 0%	0 0%
JAN-2018	0 0%	0 0%	9 47%	2006 60%	8 42%	631 19%	0 0%	46 1%	2 11%	688 21%	0 0%	0 0%
FEB-2018	0 0%	0 0%	16 70%	2027 60%	6 26%	642 19%	0 0%	45 1%	1 4%	676 20%	0 0%	0 0%
MAR-2018	0 0%	0 0%	14 93%	2061 61%	1 7%	646 19%	0 0%	43 1%	0 0%	674 20%	0 0%	0 0%
APR-2018	0 0%	0 0%	8 73%	2106 61%	3 27%	654 19%	0 0%	44 1%	0 0%	681 20%	0 0%	0 0%
MAY-2018	0 0%	0 0%	13 65%	2140 61%	4 20%	666 19%	1 5%	42 1%	3 15%	675 19%	0 0%	0 0%
JUN-2018	0 0%	0 0%	7 64%	2175 62%	3 27%	675 19%	0 0%	42 1%	1 9%	678 19%	0 0%	0 0%
JUL-2018	0 0%	0 0%	7 58%	2209 62%	4 33%	674 19%	0 0%	43 1%	1 8%	677 19%	0 0%	0 0%
AUG-2018	0 0%	0 0%	23 79%	2255 63%	5 17%	671 19%	0 0%	42 1%	1 3%	671 19%	0 0%	0 0%
SEP-2018	0 0%	9 0%	5 36%	2266 62%	9 64%	688 19%	0 0%	41 1%	0 0%	656 18%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1754	24.41	2223	30.94	134	1.86	58	0.81	884	12.30
APR-2017	2109	29.38	1744	24.30	2260	31.49	133	1.85	59	0.82	873	12.16
MAY-2017	2108	29.18	1737	24.04	2308	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2115	29.19	1719	23.73	2349	32.42	132	1.82	59	0.81	871	12.02
JUL-2017	2102	29.03	1694	23.39	2386	32.95	130	1.80	62	0.86	867	11.97
AUG-2017	2094	28.82	1687	23.22	2408	33.14	130	1.79	61	0.84	886	12.19
SEP-2017	2074	28.72	1676	23.21	2427	33.61	127	1.76	57	0.79	861	11.92
OCT-2017	2050	28.30	1674	23.11	2476	34.18	124	1.71	57	0.79	863	11.91
NOV-2017	2004	27.68	1668	23.04	2519	34.79	119	1.64	56	0.77	875	12.08
DEC-2017	1998	27.65	1660	22.97	2531	35.02	115	1.59	56	0.77	867	12.00
JAN-2018	2009	27.55	1645	22.56	2595	35.59	117	1.60	55	0.75	871	11.94
FEB-2018	1968	27.12	1630	22.46	2615	36.04	116	1.60	59	0.81	868	11.96
MAR-2018	1981	27.21	1616	22.19	2647	36.35	113	1.55	56	0.77	868	11.92
APR-2018	1939	26.69	1596	21.97	2698	37.13	114	1.57	58	0.80	861	11.85
MAY-2018	1932	26.51	1575	21.61	2738	37.57	114	1.56	58	0.80	871	11.95
JUN-2018	1913	26.22	1565	21.45	2791	38.26	113	1.55	58	0.80	855	11.72
JUL-2018	1889	25.89	1568	21.49	2818	38.62	110	1.51	55	0.75	857	11.74
AUG-2018	1865	25.59	1548	21.24	2859	39.23	110	1.51	56	0.77	850	11.66
SEP-2018	1827	25.21	1531	21.12	2880	39.74	108	1.49	59	0.81	843	11.63

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2017	21	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510
SEP-2017	16	1	2	3	3	5	440
OCT-2017	6	2	0	0	2	2	435
NOV-2017	19	2	1	6	3	7	430
DEC-2017	18	2	2	4	4	5	390
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	22	4	1	5	4	7	350
APR-2018	14	0	0	4	2	5	490
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	15	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2017	11555	3375
FEB-2017	11580	3382
MAR-2017	11631	3431
APR-2017	11657	3446
MAY-2017	11698	3471
JUN-2017	11725	3485
JUL-2017	11757	3515
AUG-2017	11793	3542
SEP-2017	11820	3567
OCT-2017	11877	3621
NOV-2017	11889	3620
DEC-2017	11916	3626
JAN-2018	11974	3668
FEB-2018	12003	3682
MAR-2018	12031	3711
APR-2018	12061	3741
MAY-2018	12097	3766
JUN-2018	12109	3769
JUL-2018	12137	3795
AUG-2018	12153	3792
SEP-2018	12179	3817

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
September 2018

N = 7248

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2018

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2018

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2018

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2018

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	40	53	25
KOOTENAY BOUNDARY	0-19	*	*	0
	20-34	*	*	0
	35-49	*	*	10
	50+	*	*	40
Total HSDA:	69	92	50	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	358	479	268	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	16
	35-49	*	*	42
	50+	*	*	83
Total HSDA:	189	251	141	
Total HA:		656	875	484

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		656	875	484

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	515	695	385
Female	141	180	99

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	484	54	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	*
	5 years or more	7	*
	<5 years	15	*
	Total HSDA:	40	25
KOOTENAY BOUNDARY	10 years or more	42	29
	5 years or more	14	11
	<5 years	13	10
	Total HSDA:	69	50
OKANAGAN	10 years or more	220	157
	5 years or more	61	51
	<5 years	77	60
	Total HSDA:	358	268
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	100	66
	5 years or more	41	35
	<5 years	48	40
	Total HSDA:	189	141
Total HA:		656	484

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	380	263
	5 years or more	123	101
	<5 years	153	120
Total HA:		656	484

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	39	57	12	21
KOOTENAY BOUNDARY	66	119	21	42
OKANAGAN	209	782	60	276
THOMPSON/CARIBOO/SHUSWAP	125	483	35	137
Total:	439	1441	128	476

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	91

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	5	5	5
	20-34	29	31	20
	35-49	112	124	77
	50+	209	280	167
	Total HSDA:	355	440	269
FRASER NORTH	0-19	10	10	*
	20-34	117	118	*
	35-49	350	386	*
	50+	526	834	*
	Total HSDA:	1003	1348	777
FRASER SOUTH	0-19	7	7	5
	20-34	106	108	75
	35-49	339	391	274
	50+	502	740	419
	Total HSDA:	954	1246	773
Total HA:		2312	3034	1819

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	22	22	12
	20-34	252	257	182
	35-49	801	901	623
	50+	1237	1854	1002
Total HA:		2312	3034	1819

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1757	2332	1416
Female	555	702	403

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1819	51	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	189	141
	5 years or more	94	73
	<5 years	72	55
	Total HSDA:	355	269
FRASER NORTH	10 years or more	520	376
	5 years or more	259	207
	<5 years	224	194
	Total HSDA:	1003	777
FRASER SOUTH	10 years or more	493	396
	5 years or more	229	184
	<5 years	232	193
	Total HSDA:	954	773
Total HA:		2312	1819

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1202	913
	5 years or more	582	464
	<5 years	528	442
Total HA:		2312	1819

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	136	481	37	76
FRASER NORTH	244	1521	55	236
FRASER SOUTH	210	1305	44	354
Total:	590	3307	136	666

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	201
FRASER NORTH	660
FRASER SOUTH	535
Total:	1396

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	17
	35-49	*	*	71
	50+	*	*	190
	Total HSDA:		330	475
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		162	211
VANCOUVER	0-19	36	39	6
	20-34	430	442	311
	35-49	1455	1644	1061
	50+	2703	4588	2047
	Total HSDA:	4624	6713	3425
Total HA:		5116	7399	3829

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	39	42	7
	20-34	479	492	344
	35-49	1584	1787	1167
	50+	3014	5078	2311
Total HA:		5116	7399	3829

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4496	6489	3383
Female	618	908	446

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3829	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	174	141
	5 years or more	80	67
	<5 years	76	70
	Total HSDA:	330	278
RICHMOND	10 years or more	85	65
	5 years or more	41	32
	<5 years	36	29
	Total HSDA:	162	126
VANCOUVER	10 years or more	2577	1833
	5 years or more	1205	903
	<5 years	842	689
	Never on ART	0	0
	Total HSDA:	4624	3425
Total HA:	5116	3829	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2836	2039
5 years or more	1326	1002
<5 years	954	788
Never on ART	0	0
Total HA:	5116	3829

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	165	482	57	178
RICHMOND	43	279	14	91
VANCOUVER	580	10593	201	5365
Total:	788	11354	272	5634

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	119

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		309	435
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		120	159
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		707	999
Total HA:		1136	1593	870

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	99	105	*
	35-49	299	348	*
	50+	731	1133	*
Total HA:		1136	1593	870

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	934	1310	724
Female	202	283	146

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	870	54	520	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	161	132
	5 years or more	71	54
	<5 years	77	60
	Total HSDA:	309	246
NORTH VANCOUVER ISLAND	10 years or more	64	52
	5 years or more	33	22
	<5 years	23	17
	Total HSDA:	120	91
SOUTH VANCOUVER ISLAND	10 years or more	394	276
	5 years or more	157	128
	<5 years	156	129
	Total HSDA:	707	533
Total HA:		1136	870

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	619	460
	5 years or more	261	204
	<5 years	256	206
Total HA:		1136	870

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	189	830	76	192
NORTH VANCOUVER ISLAND	127	256	41	71
SOUTH VANCOUVER ISLAND	204	1721	43	554
Total:	520	2807	160	817

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	46
NORTH VANCOUVER ISLAND	33
SOUTH VANCOUVER ISLAND	104
Total:	183

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		39	47
NORTH WEST	0-19	*	*	0
	20-34	*	*	9
	35-49	*	*	14
	50+	*	*	30
	Total HSDA:		67	105
NORTHERN INTERIOR	0-19	5	5	*
	20-34	19	22	*
	35-49	72	88	*
	50+	86	142	*
	Total HSDA:		182	257
Total HA:		288	409	212

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	33	38	*
	35-49	107	142	*
	50+	141	222	*
Total HA:		288	409	212

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	177	254	131
Female	111	155	81

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	212	50	555	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	9
	5 years or more	14	9
	<5 years	8	6
	Total HSDA:	39	24
NORTH WEST	10 years or more	26	17
	5 years or more	27	25
	<5 years	14	11
	Total HSDA:	67	53
NORTHERN INTERIOR	10 years or more	67	45
	5 years or more	66	53
	<5 years	49	37
	Total HSDA:	182	135
Total HA:		288	212

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	110	71
5 years or more	107	87
<5 years	71	54
Total HA:	288	212

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	37	61	8	9
NORTH WEST	69	155	16	28
NORTHERN INTERIOR	103	442	15	188
Total:	209	658	39	225

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	19
NORTHERN INTERIOR	18
Total:	43

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	22	37	*
	THOMPSON/CARIBOO/SHUSWAP	26	44	*
	Total HA:	60	100	44
FRASER	FRASER EAST	40	50	29
	FRASER NORTH	56	91	47
	FRASER SOUTH	67	98	49
	Total HA:	163	239	125
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	49	24
	RICHMOND	11	16	9
	VANCOUVER	495	839	392
	Total HA:	532	904	425
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	48	76	38
	NORTH VANCOUVER ISLAND	16	25	12
	SOUTH VANCOUVER ISLAND	33	75	25
	Total HA:	97	176	75
NORTHERN	NORTH EAST	9	11	8
	NORTH WEST	32	61	29
	NORTHERN INTERIOR	65	101	50
	Total HA:	106	173	87
Total:		958	1592	756

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	599	1018	476
Female	359	574	280

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	756	51	500	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

